ELI LILLY

Analysis before buying or selling Eli Lilly shares

Trade the Eli Lilly share!

BUY

SELL

79% of retail CFD accounts lose money - eToro.com

Chart provided by Tradingview

Many traders are interested in Eli Lilly's US stock and wish to invest in its share price, particularly through CFDs. If this is also the case for you, this article will tell you everything you need to know about the company to make a good analysis of this stock. In particular, you will discover the details of the group's activities, its main sources of profit, its direct and indirect competitors on the market and its allies with a few examples of recent partnerships. We will also guide you in carrying out your fundamental analysis of this stock.

Can I receive dividends when I buy Eli Lilly shares?

Yes

ISIN code: US5324571083

Ticker: NYSE: LLY

Index or market: NYSE

How to buy and sell Eli Lilly shares with eToro?

Open an account by clicking here

Deposit Funds

Search Eli Lilly (NYSE: LLY)

Buy/Sell Eli Lilly shares

79% of retail CFD accounts lose money - eToro.com

Elements to consider before selling or buying Eli Lilly shares

Analysis N°1

First of all, we will monitor the improvement in living standards and purchasing power around the world, on which a large part of Eli Lilly's business depends.

Analysis N°2

The growing awareness of health needs is also an element on which you can base your anticipations.

Analysis N°3

The ageing of the world's population is also an indicator to follow if you wish to take a position on this value.

Analysis N°4

We will also monitor the evolution of the market shares of generic drugs that are in direct competition with the drugs developed by Eli Lilly.

Analysis N°5

The global economic health will also influence the sales of this group.

Analysis N°6

Finally, we will of course also monitor the group's investments in R&D in the context of the development of new innovative treatments.

Analysis before buying or selling Eli Lilly shares

Buy Eli Lilly CFD shares

Sell Eli Lilly CFD shares

79% of retail CFD accounts lose money - eToro.com

General presentation of Eli Lilly

Let us now set off together to discover Eli Lilly and its various activities. This will allow you to understand how this value may behave in the coming months and years depending on the company's sources of revenue.

The Eli Lilly Group is an American company specialising in the pharmaceutical sector and is also one of the world leaders in this sector. In order to better understand the activities of this group, it is possible to divide them into different divisions according to the share of turnover they generate and in this way :

Endocrinology generates 47.6% of the group's turnover with products to treat osteoporosis, diabetes and growth problems.
Oncology generates 17.4% of turnover.
Veterinary medicine generates 12.8% of the group's turnover.
Cardiovascular diseases represent 9.2% of turnover.
Neurology generates 7.4% of sales with drugs to treat depression and schizophrenia.
Immune diseases account for 4.6% of turnover.
Finally, the remaining 1% of turnover comes from other products.

It is also interesting to know the geographical distribution of Eli Lilly's revenues. The group generates 56.5% of its turnover in the United States, 17.2% in Europe, 10.2% in Japan and 16.1% in the rest of the world.

Photo credits: ©jetcityimage/123RF.COM

The major competitors of Eli Lilly

Let's now discover the other major global players in this sector and thus Eli Lilly's direct competitors.

Pfizer

This pharmaceutical company was founded in 1849 and operates in more than 150 countries. It is the world leader in its sector with a very large market capitalisation and turnover. Pfizer employs nearly 81,800 people worldwide.

Sanofi

This French pharmaceutical group is active in several businesses including pharmaceuticals with products in the treatment of diabetes, rare diseases, multiple sclerosis, oncology, consumer and generic health products and vaccines.

Astrazeneca

The Astrazeneca group is also one of the leaders in this pharmaceutical sector in the world. It was created in 1999 following the merger of the Swedish company Astra and the British company Zeneca.

GlaxosmithKline or GSK

This British multinational is also one of the giants of the pharmaceutical industry in the world. It was created from the merger of Glaxo Wellcome and SmithKline Beecham in 2000.

Bristol-Myers Squibb

This US pharmaceutical company has been in existence since 1989 and is the result of the merger of Bristol Myers Company and Squibb Corporation. Today and thanks to this merger, the group has become one of the largest in this sector.

Merck

The Merck Group is a German company specialising in pharmaceuticals through Merck Serono, but also in chemicals.

Roche Holding

This company is a Swiss pharmaceutical company and also one of the world's leading companies in this sector. It has been active since 2004 in two distinct sectors, including pharmaceuticals and diagnostics.

The major partners of Eli Lilly

Of course, Eli Lilly also has allies to rely on for its growth and development. We therefore invite you to discover here some of the partnerships recently set up by this company.

Dicerna Pharmaceuticals

First, Eli Lilly has signed a partnership with Dicerna Pharmaceuticals with a global licensing and research collaboration focused on the discovery, development and sale of potential new drugs for the treatment of cardiometabolic diseases, neurodegeneration or pain. The two companies plan to collaborate on the development of around ten drugs. The agreement provides for an upfront payment to Dicerna of $100 million and an equity investment of $100 million at a premium. Dicerna could also receive up to $350 million per target in development and commercialization stages.

AC Immune

Recently, Eli Lilly also signed a collaboration agreement with the Swiss company AC Immune to research and develop small molecule inhibitors of tau protein aggregation for the treatment of Alzheimer's disease and other such neurodegenerative disorders. This partnership will notably draw on AC Immune's technology platform, Morphomer, and Eli Lilly's expertise in clinical development and commercial capabilities. Initially, it will involve the molecule ACI-3024 with an initial payment of 80 million Swiss francs to AC Immune and $50 million in exchange for an option for an equity stake.

Trade the Eli Lilly share!

79% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

Frequently Asked Questions

How has the Eli Lilly share performed recently?

Before trading Eli Lilly shares, you may want to know about their recent performance. For example, the annualised yield or dividend per share currently stands at 1.70% (for the financial year 2019). It should also be noted that the change in the share price over one year is around 38.9% in positive terms. Over a longer period, i.e. over the last 5 years, this share has seen a positive variation of 116.94%.

What events have the greatest impact on Eli Lilly's share price?

Among the external events and elements that most influence the Eli Lilly share price, strategic partnerships, particularly in the field of research and development of new treatments, will of course be monitored. Announcements of the launch of new treatments that have obtained the necessary authorisations from the health authorities are also particularly interesting events on which to take a position.

Is it possible to trade Eli Lilly shares in United Kingdom?

It is of course possible to speculate on the price of Eli Lilly shares in United Kingdom as well as on the price of many other American and international shares. While foreign securities are limited in traditional stock market investment products, the CFDs or contracts for difference offered by brokers and their online trading platforms give you access to a very large quantity of these securities.

Trade the Eli Lilly share!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.